Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.

Third quarter Highlights

• Net revenues of $191.2 million for the third quarter

• GAAP net income of $40.4 million, or $0.78 per share, for the third quarter

• Adjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarter

Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI^®, which has become a cornerstone in our portfolio, and Primatene MIST^®, which is trending toward our goal of $100 million in sales per year. Looking forward, we will focus on positioning our Company towards sustainable, long-term growth by pivoting to high-value and high-growth areas, particularly centered on developing proprietary products and biosimilars, which we expect will allow us to leverage our R&D expertise and technology."

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2024				2023				2024				2023
		(in thousands, except per share data)
Net revenues		$	191,214			$	180,556			$	545,444			$	466,290
GAAP net income		$	40,429			$	49,222			$	121,555			$	101,378
Adjusted non-GAAP net income*		$	49,585			$	61,898			$	153,569			$	128,823
GAAP diluted EPS		$	0.78			$	0.91			$	2.32			$	1.91
Adjusted non-GAAP diluted EPS*		$	0.96			$	1.15			$	2.94			$	2.43

____________________________________

* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

Third quarter Results

		Three Months Ended
		September 30,								Change
		2024				2023				Dollars				%
		(in thousands)
Product revenues:
BAQSIMI®		$	40,409			$	-			$	40,409				N/A
Glucagon			26,792				29,514				(2,722	)			(9	)%
Primatene MIST®			26,055				24,834				1,221				5	%
Epinephrine			21,341				20,199				1,142				6	%
Lidocaine			15,884				15,522				362				2	%
Phytonadione			11,721				7,449				4,272				57	%
Enoxaparin			5,615				7,702				(2,087	)			(27	)%
Naloxone			4,037				4,715				(678	)			(14	)%
Other finished pharmaceutical products			35,503				37,730				(2,227	)			(6	)%
Total finished pharmaceutical products net revenues		$	187,357			$	147,665			$	39,692				27	%
API			1,462				4,190				(2,728	)			(65	)%
Other revenues			2,395				28,701				(26,306	)			(92	)%
Total net revenues		$	191,214			$	180,556			$	10,658				6	%

Changes in product revenues as compared to the third quarter of the prior year were primarily driven by:

• BAQSIMI^® revenues consisting of $40.4 million in sales made by the Company directly to its customers, which are recorded as part of product revenues, net, and $6.4 million in sales made by Eli Lilly & Company, or Lilly, on behalf of the Company under a Transition Services Agreement, or TSA, which resulted in a net payment to the Company of $2.4 million after deducting the cost of sales and other expenses and was recorded in other revenues

• Glucagon sales decreased due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMI^®, as well as a decrease in average selling price

• Primatene MIST^® sales increased primarily due to an increase in unit volumes

• Epinephrine sales increased primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter

• The increase in sales of phytonadione was primarily due to an increase in unit volume, as a result of an increase in demand during the quarter

• Enoxaparin and naloxone sales decreased primarily due to a decrease in unit volumes

• Other finished pharmaceutical product sales changes were primarily due to:

  • Lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels

  • These decreases were partially offset by:

    • Higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited

    • The launch of albuterol in August 2024

Between $2.0 million and $4.0 million in sales expected to be recognized in the third quarter were not recognized due to delayed shipments caused by the aftermath of Hurricane Helene. Revenues for these shipments are expected to be recognized in the fourth quarter.

		Three Months Ended
		September 30,								Change
		2024				2023				Dollars				%
		(in thousands)
Net revenues		$	191,214			$	180,556			$	10,658				6	%
Cost of revenues			89,273				72,153				17,120				24	%
Gross profit		$	101,941			$	108,403			$	(6,462	)			(6	)%
as % of net revenues			53.3%				60.0%

Changes in the cost of revenues and gross margin were primarily driven by:

• Increased labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value

• Decrease in other revenues related to Lilly's sales of BAQSIMI^® under the TSA, which are recorded net of cost of sales and other expenses as we assumed distribution of BAQSIMI^® to our customers and are now recording those sales in product revenues and cost of sales separately

• This was partially offset by:

  • Increase in sales of Primatene MIST^® and epinephrine, which are higher-margin products

		Three Months Ended
		September 30,								Change
		2024				2023				Dollars				%
		(in thousands)
Selling, distribution, and marketing		$	8,995			$	6,407			$	2,588				40	%
General and administrative			14,821				12,654				2,167				17	%
Research and development			21,077				16,664				4,413				26	%

• Selling, distribution, and marketing expenses increased primarily due to the expenses related to the expansion of our sales and marketing efforts related to BAQSIMI^®

• General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI^®

• Research and development expenses increased due to expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses, which was partially offset by a decrease in clinical trial expenses due to the timing of clinical trials

		Three Months Ended
		September 30,								Change
		2024				2023				Dollars				%
		(in thousands)
Non-operating income (expenses)
Interest income		$	2,427			$	1,202			$	1,225				102	%
Interest expense			(6,698	)			(13,702	)			7,004				(51	)%
Other income (expenses), net			(5,094	)			3,459				(8,553	)			(247	)%
Total non-operating income (expenses), net		$	(9,365	)		$	(9,041	)		$	(324	)			4	%

The change in non-operating income (expenses), net is primarily a result of:

• An increase in interest income resulting from an increase in cash and investments

• A decrease in interest expense was primarily due to the $250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of unamortized debt issuance costs related to the Term Loan in 2023

• A change to other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts

Cash flow provided by operating activities for the nine months ended September 30, 2024, was $184.4 million.

Share Buyback Program

On November 4, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.

The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

Pipeline Information

The Company currently has four abbreviated new drug applications ("ANDAs") on file with the U.S. Food and Drug Administration (the "FDA") targeting products with a market size of over $2.4 billion, four biosimilar products in development targeting products with a market size of over $8 billion, and three generic products in development targeting products with a market size of approximately $2 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2024. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. ("ANP"), currently has multiple Drug Master Files ("DMFs") on file with the FDA and is developing several additional DMFs.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar^®, BAQSIMI^®, Primatene MIST^®, REXTOVY^TM, Amphadase^®, and Cortrosyn^®, are the property of Amphastar.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI^®, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, November 6, 2024, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free [phone] or [phone] for international callers, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.

Forward-Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI^®, including its potential for continued revenue growth, the success of our integration of BAQSIMI^®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST^® or that we will continue to experience significant sales of BAQSIMI^®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
[phone]

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2024				2023				2024				2023
Net revenues:
Product revenues, net		$	188,819			$	151,855			$	525,836			$	437,589
Other revenues			2,395				28,701				19,608				28,701
Total net revenues			191,214				180,556				545,444				466,290
Cost of revenues			89,273				72,153				258,237				211,309
Gross profit			101,941				108,403				287,207				254,981
Operating expenses:
Selling, distribution, and marketing			8,995				6,407				27,378				20,234
General and administrative			14,821				12,654				43,782				38,418
Research and development			21,077				16,664				55,772				53,322
Total operating expenses			44,893				35,725				126,932				111,974
Income from operations			57,048				72,678				160,275				143,007
Non-operating income (expenses):
Interest income			2,427				1,202				8,320				3,156
Interest expense			(6,698	)			(13,702	)			(23,918	)			(17,702	)
Other income (expenses), net			(5,094	)			3,459				1,125				1,553
Total non-operating income (expenses), net			(9,365	)			(9,041	)			(14,473	)			(12,993	)
Income before income taxes			47,683				63,637				145,802				130,014
Income tax provision			7,254				14,025				23,674				27,160
Net income before equity in losses of unconsolidated affiliate			40,429				49,612				122,128				102,854
Equity in losses of unconsolidated affiliate			-				(390	)			(573	)			(1,476	)
Net income		$	40,429			$	49,222			$	121,555			$	101,378
Net income per share:
Basic		$	0.83			$	1.01			$	2.50			$	2.10
Diluted		$	0.78			$	0.91			$	2.32			$	1.91
Weighted-average shares used to compute net income per share:
Basic			48,621				48,701				48,580				48,368
Diluted			51,862				53,921				52,307				52,997

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)

		September 30,				December 31,
		2024				2023
		(unaudited)
ASSETS
Current assets:
Cash and cash equivalents		$	192,116			$	144,296
Restricted cash			235				235
Short-term investments			58,375				112,510
Restricted short-term investments			2,200				2,200
Accounts receivable, net			139,635				114,943
Inventories			130,316				105,833
Income tax refunds and deposits			5,349				526
Prepaid expenses and other assets			17,723				9,057
Total current assets			545,949				489,600
Property, plant, and equipment, net			295,384				282,746
Finance lease right-of-use assets			426				564
Operating lease right-of-use assets			31,708				32,333
Investment in unconsolidated affiliate			-				527
Goodwill and intangible assets, net			594,796				613,295
Long-term investments			-				14,685
Other assets			23,663				25,910
Deferred tax assets			53,252				53,252
Total assets		$	1,545,178			$	1,512,912
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	153,268			$	93,366
Accrued payments for BAQSIMI®			-				126,090
Income taxes payable			1,281				1,609
Current portion of long-term debt			252				436
Current portion of operating lease liabilities			4,209				3,906
Total current liabilities			159,010				225,407
Long-term reserve for income tax liabilities			6,066				6,066
Long-term debt, net of current portion and unamortized debt issuance costs			596,446				589,579
Long-term operating lease liabilities, net of current portion			28,941				29,721
Other long-term liabilities			27,037				22,718
Total liabilities			817,500				873,491
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023			6				6
Additional paid-in capital			496,427				486,056
Retained earnings			530,823				409,268
Accumulated other comprehensive loss			(8,821	)			(8,478	)
Treasury stock			(290,757	)			(247,431	)
Total equity			727,678				639,421
Total liabilities and stockholders' equity		$	1,545,178			$	1,512,912

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2024				2023				2024				2023
GAAP net income		$	40,429			$	49,222			$	121,555			$	101,378
Adjusted for:
Intangible asset amortization			6,179				6,168				18,539				6,651
Share-based compensation			5,596				4,644				18,736				15,620
Impairment of long-lived assets			-				474				-				3,174
Expenses related to BAQSIMI® acquisition			-				2,182				3,651				3,682
Debt issuance costs			-				3,019				-				6,043
Income tax provision on pre-tax adjustments			(2,619	)			(3,811	)			(8,912	)			(7,725	)
Adjusted non-GAAP net income		$	49,585			$	61,898			$	153,569			$	128,823
Adjusted non-GAAP net income per share:
Basic		$	1.02			$	1.27			$	3.16			$	2.66
Diluted		$	0.96			$	1.15			$	2.94			$	2.43
Weighted-average shares used to compute adjusted non-GAAP net income per share:
Basic			48,621				48,701				48,580				48,368
Diluted			51,862				53,921				52,307				52,997

		Three Months Ended September 30, 2024
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	89,273			$	8,995			$	14,821			$	21,077			$	(9,365	)		$	7,254
Intangible asset amortization			(6,159	)			-				(1	)			(19	)			-				-
Share-based compensation			(1,133	)			(249	)			(3,710	)			(504	)			-				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				2,619
Non-GAAP		$	81,981			$	8,746			$	11,110			$	20,554			$	(9,365	)		$	9,873

		Three Months Ended September 30, 2023
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	72,153			$	6,407			$	12,654			$	16,664			$	(9,041	)		$	14,025
Intangible asset amortization			(6,149	)			-				34				(53	)			-				-
Share-based compensation			(1,004	)			(213	)			(2,975	)			(452	)			-				-
Impairment of long-lived assets			(470	)			-				(4	)			-				-				-
Expenses related to BAQSIMI® acquisition			-				-				(357	)			-				1,825				-
Debt issuance costs			-				-				-				-				3,019				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				3,811
Non-GAAP		$	64,530			$	6,194			$	9,352			$	16,159			$	(4,197	)		$	17,836

		Nine Months Ended September 30, 2024
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	258,237			$	27,378			$	43,782			$	55,772			$	(14,473	)		$	23,674
Intangible asset amortization			(18,479	)			-				(4	)			(56	)			-				-
Share-based compensation			(4,583	)			(777	)			(11,239	)			(2,137	)			-				-
Expenses related to BAQSIMI® acquisition			-				-				-				-				3,651				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				8,912
Non-GAAP		$	235,175			$	26,601			$	32,539			$	53,579			$	(10,822	)		$	32,586

		Nine Months Ended September 30, 2023
						Selling,				General				Research				Non-operating
		Cost of				distribution				and				and				(expenses)				Income
		revenue				and marketing				administrative				development				income, net				tax provision
GAAP		$	211,309			$	20,234			$	38,418			$	53,322			$	(12,993	)		$	27,160
Intangible asset amortization			(6,582	)			-				(16	)			(53	)			-				-
Share-based compensation			(3,868	)			(649	)			(9,323	)			(1,780	)			-				-
Impairment of long-lived assets			(3,170	)			-				(4	)			-				-				-
Expenses related to BAQSIMI® acquisition			-				-				(1,857	)			-				1,825				-
Debt issuance costs			-				-				-				-				6,043				-
Income tax provision on pre-tax adjustments			-				-				-				-				-				7,725
Non-GAAP		$	197,689			$	19,585			$	27,218			$	51,489			$	(5,125	)		$	34,885

SOURCE: Amphastar Pharmaceuticals, Inc.

View the original press release on accesswire.com